Investment
Features
FeesSafety
Academy
More
Pluang+

THORChain struggles to block stolen $387.5M from Bitget hack due to validator coordination delays.

Market News
06 Oct 2026
Tokenpost
View Source
Bearish
THORChain struggles to block stolen $387.5M from Bitget hack due to validator coordination delays.

THORChain co-founder Chad Barraford explained that coordinating validators to block funds stolen in Bitget's $387.5 million hack can take days to weeks, allowing attackers time to move assets. The protocol's trading pauses affect the entire network rather than targeting individual wallets, limiting selective intervention. Stopping ongoing swaps may require a complex vault migration needing two-thirds validator approval, further delaying response. This situation highlights the challenge of balancing theft prevention with avoiding disruption to legitimate users on THORChain's decentralized network.

THORChain validator coordination delays are the subject here; for readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 06, 2026 23:03 WIB: out of 50 major cryptocurrencies priced on Pluang, 25 rose and 24 fell today. Notable movers include BAL (Balancer) at Rp16.297 with an 11.14% increase, EOS (EOS.IO) at Rp12.649 up 8.13%, and FIL (Filecoin) at Rp20.810 rising 6.64% with a strong 80% buy order activity. The most notable figure is BAL's 11.14% gain.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
22 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App